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The T lineage glycoprotein CD6 is generally considered to be a costimulator of T-cell
activation. Here, we demonstrate that CD6 signiﬁcantly reduces early and late T-cell
responses upon superantigen stimulation or TCR triggering by Abs. Measuring calcium
mobilization in single cells responding to superantigen, we found that human T cells
expressing rat CD6 react signiﬁcantly less well compared with T cells not expressing the
exogenous receptor. When the cytoplasmic domain of rat CD6 was removed, calcium
responses were recovered, indicating that the inhibitory properties of CD6 are attributable
to its cytoplasmic domain. Calcium responses, and also late indicators of T-cell activation
such as IL-2 release, were also diminished in TCR-activated Jurkat cells expressing human
CD6, compared with CD6-deﬁcient cells or cells expressing a cytoplasmic deletion mutant
of human CD6. Similarly, calcium signals triggered by anti-CD3 were enhanced in human
T lymphocytes following morpholino-mediated suppression of CD6 expression. Finally,
the proliferation of T lymphocytes was increased when the CD6–CD166 interaction was
blocked with anti-CD166 Abs, but inhibited when anti-CD6 Abs were used. Our data
suggest that CD6 is a signaling attenuator whose expression alone, i.e. in the absence of
ligand engagement, is sufﬁcient to restrain signaling in T cells.
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CD6 is an integral membrane protein expressed on peripheral
T lymphocytes and medullary thymocytes [1]. CD6 is likely to be
involved in the regulation of T-cell development and activation
[2], and to have an important role in the context of human
inﬂammatory responses and cellular expansions, given that the
CD6 gene is strongly associated with susceptibility to multiple
sclerosis (MS) according to genome-wide association studies and
meta analyses [3, 4]. Anti-CD6 IgM Abs have been used in clinical
trials with MS patients, although they are yet to have a clinical
impact [5]. Given this level of clinical interest, however, it is of
considerable importance that the signaling pathways regulated
by CD6 are better characterized.
CD6 has long been regarded as a costimulatory molecule
largely because Ab-mediated CD6 cross-linking potentiates
proliferative T-cell responses [6, 7], and also because soluble,
monomeric CD6 present in antigen (Ag)-primed mixed
lymphocyte reactions inhibited Ag-speciﬁc T-cell responses
[8–10]. Upon TCR engagement, CD6 is phosphorylated on tyro-
sine residues suggesting that interactions with SH2 domain-
containing intracellular mediators very likely occur [11]. The
cytoplasmic domain of CD6 additionally contains multiple
potential binding sites for SH3 domain-containing signaling
effectors [12]. Accordingly, the rat homologue of CD6 has the
capacity to associate with protein tyrosine kinases of different
families, such as the Src-family kinases Lck and Fyn, the Syk
family kinase ZAP-70, and the Tec-family kinase Itk [13]. Beyond
this neither the signaling pathways directly triggered by CD6
stimulation nor even the character of the resulting signals is well
understood.
Recent studies have shown that CD6 associates with SLP-76, a
positive regulator of T-cell activation [9], and with the scaffold-
ing protein syntenin-1, possibly coupling CD6 to the cytoskeleton
and other signaling effectors [14]. CD6 has also been shown to
associate at the surface of T cells with the structurally
related receptor CD5 [13, 15], an inhibitor of T-cell responses
[16–18]. CD5 and CD6 exhibit a shared pattern of expression
during ontogeny, and the possibility of overlapping effects of
these two proteins on repertoire selection has been previously
suggested [19]. Moreover, stimulation of rat T cells with anti-
CD6 Abs enhanced the tyrosine phosphorylation of CD5 [13],
suggesting that CD6 triggering may increase the inhibitory
potential of CD5.
The molecular basis of the interaction between CD6 and its
physiological ligand, CD166, has been comprehensively studied
[2]. CD166 is expressed on cortical and medullary thymic
epithelial cells, monocytes and transiently on activated leuko-
cytes, indicating that the contact between CD6 and CD166 may
be important during thymic selection and during and after the
activation of mature T cells [9, 20]. CD6 is also reported to
accumulate at the immunological synapse upon T cell–APC
conjugate formation [8], with the interaction depending on the
binding of APC-expressed CD166 to the third scavenger receptor
cysteine-rich extracellular domain of CD6 [21].
We have investigated the signaling role of CD6 during Ag
presentation and in vitro stimulation. Surprisingly, contrary to
expectation based on the effects of CD6 cross-linking, which
activates T cells [6, 7, 13], we consistently observe that the
expression of CD6 at the surface of T cells abrogates both early
and late signaling responses triggered by Ag or by direct stimu-
lation of the TCR/CD3 complex, even in the absence of ligand
binding. Our results strongly suggest that, as in the case of the
evolutionarily related molecule CD5, CD6 is a negative modulator
of T-cell activation whose expression alone at the T-cell surface is
sufﬁcient to constrain T-cell activation.
Results
CD6 expression inhibits calcium responses in T cells
To investigate the signaling role of CD6, we used ex vivo human
T lymphocytes and induced the expression of exogenous
rat CD6 (rCD6) at their cell surface. We then measured calcium
responses of individual T cells, either expressing or not rCD6,
interacting with superantigen (sAg)-loaded APCs. Transient
manipulations of T-cell signaling molecules in this system have
been useful for identifying critical parameters for T-cell activation
previously [22].
Following transfection with a cDNA encoding rCD6
fused to YFP, the human T cells expressed variable levels
of the chimeric protein (Fig. 1A, top panel). Endogenous human
CD6 (hCD6) as well as human CD3 (hCD3) were highly
expressed and their expression was unaffected by the coexpres-
sion of rCD6 (Fig. 1A, middle and bottom panels, respectively).
Similarly, Raji cells (used as APCs) express human CD166
(hCD166), and so presumably in T cell–APC conjugates, T-cell
surface hCD6 interacts with hCD166 expressed in Raji
cells. We have considered untransfected T cells interacting with
untransfected Raji the standard experimental setting, and chan-
ges that may occur following the expression of rCD6 and rCD166
should be due to speciﬁc functions of these heterologous rat
molecules.
T cells were allowed to interact with sAg-loaded Raji cells, and
intracellular calcium levels in individual T-cell/Raji cell conju-
gates were followed by ﬂuorescence imaging. Strikingly,
T cells expressing high levels of exogenous rCD6 appeared to be
much less responsive to APCs than T cells that were low or
negative for rCD6; a typical example is shown in Fig. 1B (see also
Supporting Information movie 1). To quantitate this effect, we
selected T cells expressing either high levels of rat CD6 (rCD6
1),
or cells for which rCD6 expression was not detectable in the
ﬂuorescence microscope (rCD6
 ). Sixty percent of rCD6
1 cells
failed to respond to the APCs, compared with only 36% of the
rCD6
  cells (Fig. 1C). For the responding cells of both the rCD6
1
and the rCD6
  groups, we measured the calcium signals in
individual cells. On average, rCD6
1 cells (n510) displayed
lower calcium signals than rCD6
  cells (n512), and the response
returned to baseline more quickly (Fig. 1D). The peak levels of
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1 cells
than those of the rCD6
  cells (po 0.05; Fig. 1E).
To determine whether endogenous hCD6 would exhibit
comparable inhibitory behavior in these cells, we suppressed its
expression using hCD6-speciﬁc morpholino oligomers (MOs); we
were successful in reducing expression by over 95% as assessed
by western blotting (Fig. 2A). Using CD3 mAb (OKT3), we acti-
vated the untransfected T cells as well as T cells treated with the
MOs, and measured calcium mobilization. At 1mg/mL to activate
3 10
6 cells/mL, OKT3 induced a very modest increase in
calcium in hCD6-expressing T cells, whereas a pronounced
increase in calcium signaling was observed in the hCD6-depleted
T cells (Fig. 2B), conﬁrming the observations made for the rCD6
transfections.
Localization of CD6 at the immune synapse is not
required for the inhibition of calcium signaling
In order to promote rCD6 localization to the immune synapse
(IS), we transfected Raji cells with a cDNA-encoding rat CD166
(rCD166) fused to CFP. As expected, when Raji cells lacked
expression of rCD166, rCD6 in T cells was distributed homo-
geneously over the cell surface and there was no particular
enrichment at the IS (Fig. 3A, upper panels). In contrast, for Raji
cells expressing rCD166, both the rCD6 expressed by the T cells
and the rCD166 expressed by the Raji cells accumulated in the
contact area (Fig. 3A, bottom panels). Measurements of calcium
mobilization in rCD6
1 cells establishing contacts with Raji cells
expressing rCD166 (rCD166
1; n516) or not expressing rCD166
Figure 1. CD6 decreases the amplitude of Ca
21 responses. (A) Cytometric analysis of ex vivo human T cells transfected with an rCD6-YFP vector.
Live cells were gated based on the Forward Scatter (FSC) and Side Scatter (SSC) proﬁles. The expression of rCD6 is indicated by a thin line (upper
panel) and the negative control is shown (in all panels) as a thick line. Expression of hCD6, (middle panel), and human CD3 (hCD3, lower panel) is
shown before (thin line) and after transfection (dashed line) of T cells with the vector. (B) Raji cells preincubated with sAg interacted with Fura-2
loaded T lymphocytes transfected with a cDNA construct encoding rCD6-YFP. Time-lapse video imaging with 20  magniﬁcation showing
superimposed differential interference contrast (DIC) and calcium signals (upper panel) and rCD6 expression (lower panel) on one rCD6
  T cells
(black arrow) and one rCD6
1 T cell (white arrow), interacting with APCs in the same ﬁeld. Scale bar510mm. (C) Percentage of rCD6
  or rCD6
1
T cells that increase (ratio 41.5) or not their calcium after conjugate formation with sAg-pulsed Raji cells. Bars represent the mean (7SD) values of
three separate experiments with at least 30 individual cells analyzed in each. (D) Intracellular calcium was measured sequentially every 10s in
T cells interacting with sAg-pulsed Raji cells. Calcium was measured for T cells expressing (dashed line) or not (solid line) rCD6-YFP. Calcium
signals were averaged from individual responses of all the cells in each set. Results are from one of the three experiments showing similar results.
(E) Dot plots showing maximal calcium signals obtained in individual cells following stimulation by sAg-loaded Raji cells. Each dot represents one
cell. Horizontal lines indicate mean values [rCD6
  (n512); rCD6
1 (n510)]. The probability that the Ca
21 signals of rCD6
1 T cells in response to sAg
stimulation were similar to those of rCD6
  T cells was assessed using Students t-test (p50.038).
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 ; n511) revealed no differences in signaling for
T cells interacting with the two sets of target cells (Fig. 3B and
Supporting Information Fig. 1A). This clearly indicates that the
localization of rCD6 at the IS per se is not required in order for it
to suppress calcium signaling.
Human CD6 does not cross-react with rat CD166
A potential complication in the interpretation of these experiments
is that hCD6, whose movement is not tracked, could interact with
the rCD166 transfected into the Raji cells. Since mouse CD166 is
reported to bind human as well as mouse CD6 [23], we investigated
whether cross-species binding between human and rat forms could
be occurring in our heterologous system. For this purpose, we
expressed the extracellular region of hCD6 and assembled
phycoerythrin-labeled CD6 tetramers that were then used to screen
for CD6 binding to rat or human CD166-expressing cells. K562 cells,
of human origin, do not express CD166, and were transfected with
cDNAs encoding rat or human CD166 (Fig. 3C). Although, as
expected, the CD166
  K562 cells did not bind the hCD6 tetramer
(Fig. 3D, left panel), hCD166-expressing K562 cells were clearly
recognized (Fig. 3D, middle panel). In contrast, rCD166-expressing
K562 cells were essentially negative for binding the hCD6 tetramers
(Fig. 3D, right panel). Additional evidence that cross-species binding
does not mediate CD6 translocation in our system is obtained from
the observation that when rCD6-expressing cells contacted Raji-
expressing rCD166 versus rCD166
  Raji, there was a clear
preference for the accumulation of rCD6 in synapses with Raji-
expressing rCD166 (Fig. 3E).
A ligand nonbinding form of CD6 suppresses calcium
responses
The experiments described above suggest that the interaction of
CD6 with its ligand does not enhance its signaling suppressing
effects. Further conﬁrmation was obtained by expressing, on
ex vivo human T cells, ratCD6Dd3 (rCD6Dd3), a natural
occurring isoform lacking domain 3, the CD166-binding domain
of rCD6 [21]. T cells expressing rCD6Dd3 fused to YFP were
allowed to form conjugates with Raji cells expressing rCD166 and
we observed that rCD6Dd3 failed to accumulate at the immune
synapse according to ﬂuorescence microscopy-based
analysis (Fig. 3F). Measurements of the calcium signals arising
in T cells that express rCD6Dd3 (n516) and interact
with Raji cells expressing rCD166, versus cells lacking the
construct (rCD6
 ; n512) indicate once again that the
expression of rCD6Dd3 downmodulates calcium signals
(Fig. 3G and Supporting Information Fig. 1B). This supports
our preceding observations, i.e. that it is the expression of CD6
per se, rather than its interactions with its ligand or its synapse
localization, that is responsible for the inhibition of calcium
signaling.
The inhibitory effects of CD6 depend on its cytoplasmic
domain
We addressed the role of the cytoplasmic domain of CD6 using an
engineered isoform of rCD6 lacking its cytoplasmic domain,
rCD6CY5 fused to YFP, which was expressed in ex vivo human
T cells. rCD6CY5 moved to the synapse when the T cells
were allowed to form conjugates with rCD166-expressing Raji
cells (data not shown). Calcium signals were measured in
individual cells conjugated with rCD166
1 Raji cells, and we
found that the fraction of T cells expressing rCD6CY5 that
increased their calcium levels following conjugate formation
(i.e.  66%; Fig. 4A) closely matched that of rCD6
  cells
(Fig. 1C). For the responding T cells expressing rCD6CY5
(n510), we measured calcium signals and compared these with
signals from responding T cells expressing full-length rCD6
(n515; Fig. 4B and Supporting Information Fig. 2). The results
indicate that rCD6-expressing cells displayed lower and more
transient calcium signals than cells expressing rCD6CY5, and
thus the inhibitory effects of CD6 can be assigned to its
cytoplasmic tail.
We have also addressed the role of hCD6, and of its cyto-
plasmic domain, by the analysis of calcium ﬂuxes in whole-cell
populations. E6.1 Jurkat cells, which already express very low
levels of hCD6, were FACS-sorted and gated on the most-negative
hCD6 cells, E6.1-hCD6
 , which were used for our assays. These
E6.1-hCD6
  cells were stably reconstituted with either full-length
hCD6, to give E6.1-hCD6-FL, or the human cytoplasmic deletion
mutant, to yield E6.1-hCD6CY5 (Fig. 4C). Before each experi-
ment, E6.1-hCD6-FL and E6.1-hCD6CY5 were FACS sorted so
that the levels of hCD6-FL and hCD6CY5, respectively, were
equivalent. We conﬁrmed by immunoprecipitation of hCD6 from
surface biotinylated cells and Western blotting, that E6.1-hCD6-
FL cells expressed only the full-length hCD6 protein ( 130kDa)
and that E6.1-hCD6CY5 cells expressed only the cytoplasmic
domain-deleted form of hCD6 ( 90kDa; Fig. 4D). Calcium
Figure 2. Expression of hCD6 downregulates calcium signals.
(A) Puriﬁed human primary T lymphocytes were treated with speciﬁc
hCD6 MOs to suppress endogenous hCD6 expression (hCD6 kd), or
with control scramble morpholinos (Control). Knockdown of hCD6 was
evaluated by Western blot of cell lysates, using b-actin as a loading
control. Numbers on the left indicate molecular mass markers (MM) in
kilodaltons (kDa). (B) Cells were incubated with calcium indicators and
after stimulation with CD3 mAb (OKT3), cells expressing hCD6
1 (grey
line) and cells where hCD6 was knocked down (hCD6
kd, black line)
were evaluated for calcium mobilization by cytometry. Data are shown
from one out of the three experiments with similar results.
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signaling. (A) Conjugates formed between sAg-pulsed Raji cells and rCD6-YFP-expressing T cells. Left panels: differential interference contrast
(DIC) images. Upper right panel: localization of rCD6 (visualized in red) when rCD166 is not expressed on the surface of Raji cells; lower right panel:
localization of rCD6 (red) and rCD166 (green) when rCD166 is expressed on the surface of Raji cells. Fluorescence overlays (yellow) of rCD6-YFP and
rCD166-CFP localization are shown. Magniﬁcation is 40 , scale bar510mm. (B) Intracellular calcium was measured in rCD6
1 T cells establishing
contacts with rCD166
1 Raji cells (thin line, n516), rCD6
1 T cells establishing contacts with rCD166
  Raji cells (dashed line, n511), or rCD6
  T cells
establishing contacts with rCD166
1 Raji cells (thick line, n515). Raji cells were previously pulsed with sAg. Averaged responses shown are from the
calcium proﬁles of individual cells from each set, from two independent experiments. (C) Expression of human CD166 in untransfected (left) or
hCD166-cDNA-transfected cells (middle), and of rat CD166 in rCD166-cDNA-transfected cells (right). Cells were gated based on the expression of
hCD166 or rCD166, respectively, and these gates were used for the analysis in (D). The negative control (Neg) is also shown. (D) Binding of hCD6
tetramers (hCD6-tet, gray lines) to untransfected K562 cells (left), K562-hCD166 cells (middle), and K562-rCD166 cells (right). Binding of hCD58
tetramers (hCD58-tet, thick lines) to the cells was used as negative control, as K562 cells do not express the hCD58 ligand, hCD2. Proﬁles of hCD58-
tet overlapped with the proﬁles of unlabeled cells (data not shown). (E) Interactions between one T cell expressing rCD6-YFP (T in red) and three
sAg-loaded Raji cells, one of which expresses rCD166-CFP (B in green) and two that do not express rCD166 (B in white). Fluorescence overlays
(yellow) of rCD6 and rCD166 localization are shown. Magniﬁcation is 40 , scale bar510mm. (F) Raji cells transfected with a rCD166-CFP vector
were pulsed with a sAg mix before incubation with ex vivo T cells expressing rCD6Dd3, a naturally occurring isoform devoid of the rCD166 binding
domain. Cells were ﬁxed after 45min of interaction. Localization of rCD166-CFP (green) and rCD6Dd3-YFP (red) as well as ﬂuorescence overlays
(yellow) are shown with a magniﬁcation of 40 . Scale bar510mm. (G) Intracellular calcium was measured sequentially every 10s in T cells
interacting with sAg-pulsed Raji cells. Calcium mobilization was measured for T cells lacking rCD6 (rCD6
 , solid line) or T cells expressing
rCD6Dd3 (dashed line), interacting with rCD166-expressing Raji cells. Averaged responses were determined from 12 rCD6
  T cells and 16 rCD6Dd3-
expressing T cells interacting with sAg-loaded Raji cells from two independent experiments.
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6
cells/mL) were similarly high in both hCD6
  cells and cells
expressing hCD6CY5, whereas cells expressing full-length hCD6
exhibited much poorer signaling capabilities (Fig. 4E), conﬁrm-
ing the cytoplasmic domain dependence of calcium signaling by
both human and rCD6.
CD6 modulates late signaling responses
We next evaluated whether CD6 was also able to exert an
inhibitory effect on downstream functional responses, such as
IL-2 production. To address this, E6.1-hCD6
  or E6.1-hCD6-FL
cells were stimulated with OKT3, or with a negative control Ab.
Following stimulation, cells expressing hCD6 produced three-fold
less IL-2 than the parental cells (Fig. 5A). We also assessed the
role of CD6 in untransfected ex vivo T cells interacting with APCs,
by testing whether blocking the CD6–CD166 interaction altered
the proliferative behavior of the T cells. Ex vivo lymphocytes were
allowed to interact with sAg-loaded Raji cells, which express
endogenous human CD166, in the presence or absence of
blocking anti-human CD166 and CD6 Abs [21]. As shown in
Fig. 5B and C, preincubating the Raji cells with the CD166 Ab
resulted in enhanced cell proliferation such that the fraction of
CD6–CD166 blocked T cells completing two rounds of prolifera-
tion after 6 days of activation was double that of control cells. In
contrast, when we blocked the interaction using a CD6 Ab,
cellular proliferation was inhibited, suggesting that binding of the
mAb to CD6 induces inhibitory signaling in the T cells (Fig. 5C).
We concluded that CD6 constrains both short-term and long-term
signaling events in T cells.
Discussion
In this report, we present evidence that, like CD5, CD6 is capable
of generating inhibitory signals in T lymphocytes. Our main
ﬁndings are (i) that transfected rCD6 and hCD6 reduce Ca
21
responses in human T cells and a T-cell line, respectively, and
that the suppression of hCD6 expression increases these
responses; (ii) that the ligand-dependent localization of CD6 to
the synapse is neither required for these effects nor, surprisingly,
further enhances them; (iii) that the cytoplasmic domains of
human and rCD6 are responsible for these inhibitory effects;
and (iv) that, in addition to receptor proximal signaling, CD6
expression suppresses longer term events such as cytokine
secretion and T-cell proliferation. We conclude from these
experiments that CD6 has an important role in establishing
thresholds for T-cell activation.
CD6 was previously regarded to be a costimulatory receptor
however, this assumption was largely built on reports by
ourselves and others in which CD6 was cross-linked together with
the TCR using Abs [6, 7, 13]. An explanation for these observa-
tions is that CD6 associates with protein tyrosine kinases such as
Lck, Fyn, and ZAP-70 [13], and it could be expected that mAb-
induced coaggregation of CD6 with the TCR might promote the
Lck/Fyn-mediated phosphorylation of CD3 ITAMs, leading to
signaling. CD5 was originally proposed to be a costimulatory
Figure 4. The inhibitory role of CD6 is dependent on its cytoplasmic
domain. (A) Percentage of calcium responsive (ratio 41.5) or un-
responsive (ratio o1.5) T cells expressing a rCD6 cytoplasmic deletion
mutant (rCD6CY5-YFP), after conjugate formation with sAg-pulsed Raji
cells. Bars represent the mean (7SD) values of three separate
experiments with at least 30 individual cells analyzed in each.
(B) Calcium signals were acquired sequentially every 10s from
rCD6CY5-YFP T cells (solid line) versus rCD6
1 T cells (expressing full-
length rCD6, dashed line), interacting with sAg-pulsed Raji cells.
Averaged responses were determined from 15 rCD6
1 T cells and 10
rCD6CY5-expressing T cells interacting with sAg-loaded Raji cells.
Results are from one of two experiments, both gave similar results.
(C) Surface expression of hCD6 in untreated E6.1 Jurkat cells (top), in
Jurkat cells following transfection with a cDNA construct encoding
full-length hCD6 (hCD6-FL) (middle), and in Jurkat cells following
transfection with a cDNA construct encoding a cytoplasmatic deletion
mutant of hCD6 (hCD6CY5) (bottom). Live cells were gated based on the
FSC and SSC proﬁles. (D) E6.1-hCD6-FL and E6.1-hCD6CY5 cells were
cell-surface biotinylated, lysed in detergent, and CD6 species were
immunoprecipitated using MEM-98 mAb and run on SDS-PAGE. (E) E6.1
Jurkat cells expressing hCD6-FL (black lines) or hCD6CY5 (gray lines),
and CD6
  cells (dashed lines) were preincubated with the calcium
indicators Fluo-3 and Fura-red and, upon anti-CD3 stimulation, total
intracellular calcium levels were monitored by cytometry during 5min.
Results are from one of three experiments, all gave similar results.
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shown to inhibit T-cell activation and thymocyte selection [18].
More recent studies have shown that blocking the
CD6–CD166 interaction with soluble recombinant ligands or Abs
reduces T-cell activation and proliferation following the interac-
tion of T cells with APCs [8–10, 26], supporting a costimulatory
role for CD6. In these experiments, however, the blocking Abs
and recombinant proteins used signiﬁcantly diminished the
number of T cell–APC conjugates that formed, implying that the
observed inhibitory effects were not simply due to the blockade of
costimulatory processes. Zimmerman et al. [10] observed that a
nonblocking CD6 mAb (M-T605) that targets domain 1 of CD6
rather than the ligand-binding domain 3, and therefore ought not
to block the CD6/CD166 interaction, is a potent inhibitor of T-cell
proliferation. Almost complete inhibition of proliferation was also
observed in cultures in which soluble CD166-Fc was used as a
blocking agent, whereas the inhibition was much less pronounced
when a CD6–Fc fusion protein was used. Similarly, Montero and
colleagues showed that in the cultures of T cells interacting with
plate-bound recombinant CD166 and CD3 mAb, the inclusion of a
nonblocking CD6 domain 1-binding Ab markedly reduced intra-
cellular phosphorylation and strongly inhibited T-cell prolifera-
tion [27]. Given that only the reagents that interact directly with
the CD6 molecule completely abolish T-cell activation, it seems
reasonable to propose that in these experiments engaging CD6
delivers a negative signal to the T cells, as is now more exhaus-
tively documented in the present experiments.
However, it is also possible that CD6 engagement strengthens
T-cell activation, albeit indirectly. The interaction of CD6 with
CD166 is fairly strong [9], and is likely to increase cellular
adhesion and in this way enhance T-cell responses. Thus, a dual
function for CD6 could be envisaged, whereby the balance of
positive (stronger adhesion) and negative (inhibitory signaling)
processes ﬁne-tunes T-cell activation. Hassan et al., while show-
ing that the interaction between CD6 and CD166 is important for
T-cell activation, have reported that an increase in the level of
CD6 expression made T cells less responsive [26], in agreement
with our present observations. The overall balance between
inhibitory and activatory signals, including the strength of the
signals initiated by the TCR, is likely to dictate the outcome of the
activation process.
The molecular mechanisms through which CD6 constrains
signaling are not yet determined, but it is possible that CD6
functions in a similar way of CD5, coupling with inhibitory
tyrosine phosphatases, e.g. SHP-1, or modulating the activity of
signaling-enhancing tyrosine kinases [28, 29]. Alternatively,
given that CD6 associates with several kinases, it might sequester
Figure 5. CD6 limits late signaling events. (A) IL-2 production (pg/mL)
by hCD6
  versus hCD6-expressing (hCD6-FL) E6.1 cells, treated (white
bars) or not treated (black bars) with OKT3. Data shown are mean195%
conﬁdence intervals from three independent experiments. The prob-
ability that the production of IL-2 by hCD6
  and hCD6FL E6.1 cells was
similar, with and without anti-CD3 mAb stimulation, was assessed
using Student’s t-test (for p–values, see graph). (B) CFSE-preincubated
human PBLs were allowed to interact for 6 days with sAg-pulsed Raji
cells expressing endogenous human CD166, in the presence of
blocking (anti-CD166-3A6 and anti-CD6-OX126) or nonblocking
(control) Abs. Cell division was determined by the extent of CFSE
dilution. (C) Effect of CD6 expression on cell proliferation. An equal
number of cells were analyzed by FACS following CFSE labeling.
Stacked bars represent the mean number of cells in each generation
(G0–G2) from three independent experiments. The probability that the
proportion of cells in G0–G2 was the same in hCD6-FL-expressing cells
in the presence of control or blocking (anti-CD166-3A6; [p o 0.0001], anti-
CD6-OX126; [p o 0.0001]) Abs was assessed using the w
2-test. p o 0.0001.
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analogously to the IgSF glycoprotein CD2, which transduces
mitogenic signals via its association with lipid rafts and the
tyrosine kinases Lck and Fyn [30, 31], and inhibitory signals via
its association with CD5 [32–34]. Since CD5 and CD6 also
associate at the surface of T cells and one major effect of CD6
stimulation is the phosphorylation of CD5 [13], it is feasible that
CD5 can integrate or transform the signals generated by the
triggering of CD6.
A striking ﬁnding of the present study is that CD6 appears to
be capable of strong inhibitory signaling in the absence of ligand.
Our ﬁndings suggest that CD6 is a general attenuator of T-cell
activation, whose level of expression at the plasma membrane,
rather than its interactions with ligand or localization at the
immunological synapse, determines the amplitude of the signal.
At present, we are unable to offer an explanation for why the
localization of CD6 to the synapse does not induce stronger
inhibitory signaling. A correlation between the levels of CD6
expression and the heightened inhibition of cell responsiveness
has been proposed previously [9]. However, given that very few
T cells do not express CD6, ﬁner-grain regulation may be
achieved by the generation of CD6 intracellular isoforms
produced at distinct stages of activation or differentiation [12,
35, 36]. Since, as we show, the cytoplasmic domain is crucial for
the inhibitory role of CD6, variation in its composition may
translate into different associations with effector molecules that
could very conceivably ﬁne-tune activation thresholds in T cells.
Nevertheless, the full-length isoform seems to be the most
abundant, and hence at least at some stages of immune respon-
ses, CD6 will display some capacity for downmodulating
activation signals as was shown for the full-length constructs
used in the present study. As the cytoplasmic part of CD6 is highly
tyrosine phosphorylated after T-cell activation, the example of
CD5 could be followed [16, 17], with a systematic and careful
analysis of the various tyrosine residues present within the
domain of CD6 undertaken. The observation that, like CD6, CD5
also attenuates signaling in T and B cells stimulated via their
physiological receptors in a ligand independent manner, suggests
that CD6 is not alone in its capacity to establish activation
thresholds via its expression per se, and that this could be a
general feature of inhibitory signaling proteins.
Materials and methods
Plasmid constructs
rCD6FL/pEYFP-N1, rCD6Dd3/pEYFP-N1 lacking the ligand-bind-
ing domain of CD6, and a cytoplasmic deletion mutant,
rCD6CY5/pEYFP-N1, as well as rCD166/pECFP-N2 have been
described previously [21].
To produce a truncated form of hCD6, the expression vector
encoding full-length hCD6, CD6/pBJ-neo [12], was used as a
template for the ampliﬁcation of a PCR fragment, with a forward
primer at the beginning of the transmembrane domain (50-CAA
GGAATCTCGGGAGCTAATGCTCC-30) and a reverse primer includ-
ing the ﬁrst tyrosine residue codon of the cytoplasmic tail, followed
by a stop codon and a XbaI restriction site (50-ACTATCTAGAC
TACTACTCGAGCGGCCGCCACTGTGCTGGATATCTGCAGAATTAA
TATT-30). The PCR product was then subcloned into CD6C
Y5/pcDNA3.1/CT-GFP-TOPO [21], in the EcoRI-XbaI restriction sites.
Human CD166 cDNA was obtained from activated PBMC,
using forward (50-TAGTAGAAGCTTATGGAATCCAAGGGGG
CCAG-30) and reverse primers (50-ACAATCACAAAACTGAA
GCCCGCGGTAGTAG-30) in a PCR reaction, and cloned into the
pECFP-N2 vector in HindIII-SacII restriction sites.
Cells and transfections
Cells lines Raji [37], Jurkat E6.1 [38], K562 [39], and CHO-K1
[40] were maintained in RPMI 1640 supplemented with 10% FCS,
1mM sodium pyruvate, 2mM L-glutamine, penicillin G (50U/mL),
and streptomycin (50mg/mL). Human peripheral blood lympho-
cytes were obtained from peripheral blood of healthy donors after
centrifugation over Lymphoprep (Nycomed Pharma). Human
primary T cells were isolated from peripheral blood by centrifuga-
tion in a Ficoll gradient followed by negative depletion on
magnetic beads (T-cell negative isolation kit, Dynal Biotech).
Transient transfections of primary T lymphocytes and of Raji
cells were performed as described previously [21]. Jurkat
E6.1 cells were stably transfected as described previously [31].
K562 cells (5 10
6) were transfected with 50mg of hCD166/
pECFP-N2 or rCD166/pECFP-N2 and by electroporation at 500mF
and 875V and cultured in complete RPMI supplemented with
5mg/mL of G418 (Invitrogen) to select for positive cells.
Flow cytometry and cell sorting
Flow cytometry was performed as described previously [33].
Monoclonal Abs used were OX52 recognizing rCD6 [41], MEM-
98 recognizing hCD6 [42], and UCHT1, recognizing human CD3
[43]; polyclonal Abs were rabbit anti-mouse (RAM) FITC-labeled
(DakoCytomation) and rabbit F(ab0)2 anti-mouse RPE (Dako).
Fluorescence-activated cell sorting was performed using a
FACSAria (Becton Dickinson).
Conjugate formation and ﬂuorescence analysis
Conjugate formation and ﬂuorescence analysis were performed
as described previously [21].
Calcium measurements
Single-cell calcium measurements were performed as described
previously [22]. To measure total calcium release in human
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6 cells were
loaded with the calcium indicators Fluo-3 and Fura Red
(Molecular Probes) at the ﬁnal concentrations of 5 and 10mM,
respectively, in complete RPMI and incubated for 45min at 371C.
Basal calcium levels were analyzed by ﬂow cytometry for 10s
before samples were removed, the agonist (OKT3 at 1mg/mL)
was added, and the samples monitored for calcium release during
5min. Cells were at a concentration of 3 10
6 cells/mL. Analysis
was performed using the FlowJo software (Treestar). The ratio
FL1/FL3 was derived and plotted against time. Kinetic plots are
represented as mean of the FL1/FL3 ratio.
CD6 knockdown using MOs
Knockdown of hCD6 from T lymphocytes was achieved through
the transient transfection of CD6 MOs into T cells using Amaxa
nucleofection. In brief, 1 10
7 cells were centrifuged, resus-
pended in 100mL of prewarmed nucleofector solution, mixed
with 150mM of MOs for CD6 (MO-CD6, 50-GTCTGGAGCT
GTCTCTGGCTGCTAC-30, GeneTools), or 150mM of scramble
MO-control (MO-c; 50-GTgTGCAGCTCTCTCTGCCTGGTAC-30-
ﬂuorescein), and transferred into nucleofector cuvettes
(Amaxa/Lonza). Nucleofection was performed in a Nucleofector
II with the V-024 program. Cells were transferred to and
maintained in complete RPMI 1640 medium at 371C and used
for analysis 72h post-transfection. CD6 knockdown was
conﬁrmed by Western blotting, using MEM-98 [42] for the
detection of hCD6. Western blotting was performed as described
previously [33]. The membranes were then stripped and
restained with an Ab speciﬁc to b-actin. The densities of bands
were measured with a Quantity-One version 4.6.9 imaging
system (BioRad) and normalized with b-actin.
Cell-surface biotinylation and detection of biotinylated
CD6
Cell-surface biotinylation and detection of biotinylated CD6 was
performed as described previously [33].
Tetramer production and staining
A cDNA fragment encoding the extracellular domain of human
CD58 (residues Phe
29-Arg
213) was ampliﬁed by PCR from
template kindly provided by M. Vuong (University of Oxford)
using forward 50-TAGGGATCCACCGGTTTTTCCCAACAAATA-
TATGGT-30 and reverse oligos 50-CTAAGATCTGGATCCTCTT-
GAATGACCGCTGCTTGG-30 containing AgeI and BamHI
restriction sites, respectively. The CD58 fragment was cloned
via AgeI and BamHI sites into the lab-modiﬁed TOPO vector
containing the secretion peptide sequence (SP) from pHLsec [44]
followed by a HA-tag with AgeI and BamHI sites immediately
afterward. Fragments containing SP, HA-tag, and CD58 insert
were then cut out from the TOPO vector constructs using HindIII
and BamHI for transfer into a lab-modiﬁed version of the pEE14
vector [45] using HindIII and BclI sites, in order to obtain CD58
chimeric cDNA encoding, in the following order, SP, HA-tag,
the extracellular region of human CD58 (residues 29–213),
and BirA [46] and 6 His tag sequences. The cDNA coding
for the extracellular domain of hCD6 (residues Asp
25-Glu
398)
was ampliﬁed from CD6/pBJ-neo [12] by PCR using
forward 50-TAGTAGGGATCCGACCAGCTCAACACCAGCAGTG-30
and reverse 50-CTACTAGGATCCTTAGTGATGTCTAGACTCCCGA-
GATTCCTTGTTC-30 oligos containing BamHI restriction sites.
PCR products were puriﬁed and cloned into the BamHI-BclI sites
of the lab-modiﬁed version of pEE14, in order to obtain CD6
chimeric cDNA encoding, in the following order, SP, HA-tag, the
extracelluar region of hCD6 (residues 25–398), and BirA and
6 His tag sequences.
The CD58 and CD6 chimera constructs were transfected into
CHO-K1 cells using GeneJuice transfection reagent (Merck).
Clones resistant to 25mM methionine sulfoximine were selected
[47] and screened for soluble CD58 (sCD58-BirA-His) or CD6
(sCD6-BirA-His) chimera expression using dot blots and
Western blots. The best clones expressing sCD58-BirA-His or
sCD6-BirA-His were selected for large-scale production
of protein and grown in cell factories (Nunc). sCD58-BirA-His
and sCD6-BirA-His secreted into tissue culture supernatants were
harvested after approximately 4wk and the proteins were
extracted by metal-chelate chromatography using Ni-NTA agar-
ose (QIAGEN). The sCD58-BirA-His and sCD6-BirA-His were
eluted from the Ni-NTA agarose with 250mM imidazole in
20mM Tris-HCl, 0.5M NaCl, pH 8.0, and further puriﬁed by size-
exclusion chromatography. Soluble chimeras were then biotiny-
lated using the BirA enzyme (Avidity LLC), and incubated over-
night at room temperature with phycoerythrin (PE)-streptavidin
(Invitrogen) at a 12:1 and 6:1 molar ratio, respectively, to allow
the formation of tetrameric CD58 and CD6 complexes. The
resulting tetramers were then puriﬁed using size-exclusion
chromatography (Superose 6 HR 10/30 column) on an AKTA
FPLC.
Analysis of cytokine production and cell division
Jurkat E6.1 cells expressing hCD6 isoforms were plated at 10
5
cells/well in complete RPMI, in the presence or absence of
stimulation with OKT3 at 1mg/mL. Supernatants were collected
after 24h and assayed for IL-2 production by ELISA (Abcam)
according to the manufacturer’s protocol.
Ag-induced cell proliferation was assessed via CFSE ﬂuores-
cence. Human PBLs at 0.5 10
6/mL were incubated with 1mM
CFSE (Molecular Probes) at 371C for 15min in PBS. For blocking
the CD6–CD166 interaction, PBLs were then washed twice with
PBS 20% FCS, and incubated with OX126 for 30min at 41C.
During the same period of time, Raji cells (1 10
5) were incu-
bated with 3A6. The negative control Ab used was mouse IgG (BD
Pharmingen). PBLs were stimulated by incubation with Raji cells
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extent of CFSE dilution detected by ﬂow cytometry after 6 days of
culture.
Statistical analysis
Statistical analysis was performed using Graphpad Prism soft-
ware (Version 5.04 for Windows, Graphpad Software, La Jolla,
CA, USA). Student’s unpaired t-test was used to analyze
continuous data; a w
2-test for independence was used to analyze
noncontinuous data.
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